At Macomics we are applying our world-leading understanding of macrophage biology in developing a proprietary pipeline of first-in-class novel therapeutics that directly modulate macrophage activity.

Our validated platform, ENIGMAC™, enables us to create genetic models of disease, uncover potential novel targets driving disease, and to move quickly in developing novel treatments for diseases for which current therapeutics are severely limited or ineffective in their ability to deliver therapeutic benefits to patients.

Our focus is on diseases where human genetic and clinical evidence points to a central role for macrophages in disease in aetiology, including specific tumor subtypes, neurological conditions, fibrotic and inflammatory diseases. Our vision is to develop new approaches to targeting macrophage activity and thereby change the course of disease. We do this by exploiting genetically-evidenced disease-specific macrophage biology to effectively harness the power of macrophage direct effector functions.